Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019314 · ClinicalTrials.gov registry record · NA
Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT04019314: Completed NA study, sponsored by Mayo Clinic.
NCT04019314 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04019314, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Researchers are observing the values of proEnkephalin (PENK) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. If changes in PENK are found, physicians may predict values of change in kidney function during treatment.
Interventions
- PROCEDURE Blood Collection
- PROCEDURE Blood Volume Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2021-10-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019314
The ClinicalTrials.gov registry entry for NCT04019314 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood Collection is the first listed.
NCT04019314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04019314 about?
NCT04019314 is a clinical study titled "Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)". Researchers are observing the values of proEnkephalin (PENK) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. If changes in PENK are found, physicians may predict values of change in kidney function during treatment.
What is the current status of trial NCT04019314?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2019-06-11. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT04019314?
The interventions under investigation include: Blood Collection (PROCEDURE), Blood Volume Analysis (PROCEDURE).
Who is sponsoring clinical trial NCT04019314?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.